Here's Why Illumina (ILMN) is a Strong Value Stock

Company Overview - Illumina Inc. is a life sciences company based in San Diego, CA, providing tools and integrated systems for analyzing genetic variation and function. Its proprietary technologies offer innovative sequencing and array-based solutions for various genetic studies, serving customers including genomic research centers, academic institutions, government laboratories, hospitals, and pharmaceutical companies [11]. Investment Ratings - Illumina has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid overall performance. It also has a Value Style Score of B, supported by attractive valuation metrics such as a forward P/E ratio of 19.82, which may appeal to value investors [12]. Earnings Estimates - In the last 60 days, eight analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.08 to $4.49 per share. Illumina has demonstrated an average earnings surprise of 106.1%, highlighting its potential for exceeding expectations [12]. Investment Consideration - With a strong Zacks Rank and high Value and VGM Style Scores, Illumina is recommended for investors looking for stocks with solid fundamentals and growth potential [13].